Stock 1530 3SBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases 3SBio Inc.

Equities

1530

KYG8875G1029

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:12 2024-06-14 am EDT 		5-day change 1st Jan Change
6.27 HKD -0.63% Intraday chart for 3SBio Inc. -0.63% -16.62%
May. 29 3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection MT
Apr. 22 3Sbio Inc. Announces Management Changes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
PR
3SBio : 2023 Interim Results Presentation
PU
3SBio : 2022 ESG Report
PU
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
PR
3SBio : 2022 Interim Results Presentation
PU
3SBio : 1530.HK) _ Prospectus
PU
3SBio : 2021 ESG Report
PU
3SBio : 2021Annual Report
PU
3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses
PU
3SBIO : 2021Annual Results
PU
3SBio : Documents on Display
PU
3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
PU
3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth
PU
3SBio : PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020
PU
3SBio : Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
PU
3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212
PR
3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China
PU
3SBio : VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA
PU
3SBio : MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry
PU
3SBio : WITHDRAWAL OF LISTING OF THE ZERO COUPON CONVERTIBLE BONDS DUE 2022
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. News 3SBio Inc.
  5. Press Releases